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The intestinal microbiota has many critical roles in maintaining gastrointestinal epithelial and gastrointestinal
systemic immune homeostasis. This review provides insight into how allogeneic hematopoietic cell trans-
plantation (HCT) and its associated complications and supportive care therapies affect the microbiota.
Additionally, the review discusses how preservation and restoration of the microbiota might be advantageous
in decreasing HCT-related morbidity and mortality.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION Over the years, advances in culture-independent tech-
For over 40 years, researchers have known that the
commensal bacteria inhabiting our intestines, collectively
termed the intestinal microbiota, are important modulators
of the biology of hematopoietic cell transplantation (HCT).
Clinical studies using strategies to suppress the intestinal
microbiota to prevent acute graft-versus-host disease
(GVHD) showed considerable promise early on but eventu-
ally failed to demonstrate consistent beneﬁt. The concept of
manipulating the microbiota to improve outcomes for pa-
tients was not forgotten, but the best means of doing so has
remained unclear.edgments on page 1365.
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ty for Blood and Marrow Transplantation.niques have led to an enhanced understanding of bacterial
subtypes beyond conventional microbiologic culture tech-
niques. Sequencing of the 16S rRNA gene was developed in
the 1980s as a powerful phylogenetic tool [1]. Coupled with
subsequent genetic methodologies, including in situ hy-
bridization and PCR, 16S characterization allows rapid iden-
tiﬁcation of bacterial isolates, including potential pathogens
from clinical samples [2]. A more recent major advance has
been the advent of high-throughput sequencing modalities,
or “deep sequencing”methods, that allow characterization of
the composition of mixed bacterial samples. Deep
sequencing of 16S rRNA has yet to be used routinely in the
clinical setting because of practical barriers to implementa-
tion, including time, cost, and complexity, although newer,
more rapid techniques are being developed [3].
A role for the microbiota has thus been re-examined in
relation to a variety of clinical outcomes, ranging from
obesity and atherosclerosis, to allergies and asthma, and
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exception, with several groups recently uncovering impor-
tant relationships between the microbiota and outcomes in
HCT recipients. In this review we provide an update
regarding our knowledge of the biology of intestinal ho-
meostasis in relation to the microbiota and a summary of
recent ﬁndings implicating cross-talk between the micro-
biota and intestinal immunity that appears to have a signif-
icant impact on outcomes after HCT.
INTESTINAL EPITHELIAL HOMEOSTASIS
The human gastrointestinal (GI) tract can harbor an esti-
mated 100 trillion individual bacteria belonging to roughly
1000 species in any single individual, and 15,000 species of
bacteria have been identiﬁed from human GI samples [4].
These bacteria exist in a symbiotic relationship with their
host, and thus a critical function of the intestinal mucosa is to
enforce immunologic tolerance to these bacteria while
maintaining the potential to mount protective responses
against pathogens when necessary.
The intestinal epithelium, composed of intestinal
epithelial cells (IECs) connected by tight junctions, creates a
physical and biochemical barrier to separate luminal organ-
isms from intestinal tissues [5]. Intestinal epithelium is
organized into small ﬁnger-like projections called villi, and in
between villi are tubular invaginations called crypts. Intes-
tinal epithelial stem cells, which give rise to all subsets of
differentiated IECs, reside at the base of these crypts and are
dependent on Wnt signaling. They can develop into
specialized secretory IECs, including goblet cells, enter-
oendocrine cells, enterocytes and Paneth cells [6]. Goblet
cells secrete mucins into the intestinal lumen to form a
mucous layer that acts as a ﬁrst line of defense against mi-
crobes [7]. Paneth cells are specialized cells found within the
crypts that secrete a variety of antimicrobial peptides,
including defensins, cathelicidins, and calprotectins. These
have activity against a variety of microbes and function by
compromising the integrity of microbial cell membranes [8].
A recently described antimicrobial peptide, the C-type lectin
regenerating islet-derived protein III gamma (RegIIIg), is
secreted by enterocytes in a MyD88-dependent manner and
plays an important role in separating luminal bacteria from
the intestinal epithelial surface [9,10].
The intestinal mucosa is in contact with harmless
commensal bacteria as well as potential pathogens, thereby
functioning to immunologically survey the intestinal lumen
[11]. IECs monitor the tone of the lumen, recognizing a va-
riety of microbial products in both antigen-independent and
antigen-dependent manners to participate in coordinated
immune tolerance or, alternatively, immune response [8].
IECs express pattern-recognition receptors, including Toll-
like receptors, nucleotide-binding oligomerization domain
(NOD)-like receptors, and retinoic acid-inducible gene 1 (RIG
-I)-like receptors, for the recognition of microbial ligands or
endogenous signals associated with pathogenesis to modu-
late cellular responses [12,13]. A subpopulation of IECs called
microfold cells mediate sampling of antigens and microor-
ganisms for presentation to the mucosal immune system
[14]. Subepithelial macrophages also sample luminal con-
tents through transepithelial dendrites [15]. Dysregulation of
the surveillance mechanisms used by the intestinal mucosa
can lead to the development of inﬂammatory bowel disease
and other disorders [16].
Interestingly, many aspects of intestinal immune ho-
meostasis fail to develop in the absence of the intestinalmicrobiota. Germ-free mice, housed in sterile conditions,
show extensive defects and impaired development of gut-
associated lymphoid tissues and antibody production [17].
IECs in germ-free mice have altered patterns of microvilli
formation and decreased rates of cell turnover compared
with wild-type, leading to defective expansion of defensins
and other antimicrobial peptides.
A variety of hematopoietic cells participates in intestinal
homeostasis. Myeloid cells, including macrophages and
dendritic cells (DCs), are important mediators of both toler-
ance and protection. Nonmigratory macrophages maintain
close contact with IECs to phagocytose and mediate clear-
ance of pathogens and commensal bacteria that traverse the
epithelial barrier [18]. In response to commensal bacteria,
IECs produce cytokines via pattern-recognition receptor
signaling, promoting the development of DCs and macro-
phages with tolerogenic properties [8], including specialized
transforming growth factor-beproducing CD103þCD11bþ
DCs within the GI tract that can induce forkhead box P3
(Foxp3)-expressing regulatory T cell (Treg) expansion [19].
Upon recognition of bacteria, DCs carry antigenic material
and live bacteria to secondary lymphoid tissues, including
mesenteric lymph nodes and Peyer’s patches, and present
them to adaptive immune cells [18]. This induces the dif-
ferentiation of Tregs as well as gut-homing properties on T
cells for the recruitment of recirculating mature cells to the
original site of antigen encounter at the intestinal lamina
propria [20]. Indoleamine 2,3-dioxygenase (IDO), an enzyme
expressed byDCs andmacrophages, catalyzes the initial rate-
limiting step in tryptophan degradation. IDO is induced
during inﬂammation by inﬂammatory cytokines, such as
IFN-g, and inhibits T cell activation through the consumption
of tryptophan and subsequent expansion of Tregs, aiding in
intestinal homeostasis [21]. Germ-free mice exhibit reduced
levels of IDO, suggesting a role of the microbiota in regula-
tion of IDO [22].
T cells can also play an important role in intestinal im-
munity. Commensal bacteria mediate intestinal immune
tolerance by producing short-chain fatty acids, including
acetate, propionate, and butyrate, through the fermentation
of undigested carbohydrates. These have been shown to
induce colonic Tregs through up-regulation of gut-homing
molecules [23] and Foxp3 [24]. A subset of bacteria from
the order Clostridiales has been identiﬁed as important for
induction of colonic Tregs [25,26], potentially by up-
regulating transforming growth factor-b to support Foxp3
induction. In contrast, pathogen-associated stimuli cause
inﬂammatory responses via IL-1 and IL-6 induction, resulting
in subsequent Th1 and Th17 activation [27].
B cells are an additional arm of the immune system active
within intestinal tissues. Commensals have recently been
shown to regulate B cell development within intestinal
lamina propria [28]. IEC secretion of cytokines induces B cell
class switching to IgA in a T celleindependent and T
celledependent manner. IgA produced by local plasma cells
is transported by IECs across the epithelial barrier into the
intestinal lumen to act as another important line of defense
against microbes [8].
In addition to myeloid cells and B and T lymphocytes, the
recently described innate lymphoid cells (ILCs) [29,30] are
also important in intestinal immune homeostasis. ILCs are
classiﬁed into 3 distinct populations (groups 1, 2, and 3) on
the basis of the expression of speciﬁc transcription factors,
cell surface markers, and ability to secrete particular cyto-
kines. RORgt-expressing group 3 ILCs in the intestine have
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limiting local and systemic chronic inﬂammation. An
important function of these ILCs is to produce IL-22, an
epithelial cell regenerative factor, in response to IL-23 pro-
duced by myeloid cells [31]. In this regard, cellular mecha-
nisms activated by inﬂammation serve to protect intestinal
epithelium by restoring immune tolerance at the epithelial
interface. ILCs have also been found to produce Csf2 in
response to macrophage-derived IL-1b, resulting in DCs
producing retinoic acid to promote Treg recruitment [32].
Interactions between components of the microbiota
represent yet another line of defense against potential
pathogens. Commensal bacteria importantly function to
prevent overgrowth of potential pathogens [33]. Adding to
the complexity of microbiota composition are host and
environmental factors, which can modulate microbiota
composition and include age [34], antimicrobial use [35],
disease [36], inﬂammation [37], metabolites [38], stress [39],
and diet [40], particularly malnourishment [41,42] (Figure 1).
EFFECTS OF HCT AND GVHD ON INTESTINAL
HOMEOSTASIS
Pre-HCT conditioning typically consists of a combination
of chemotherapeutic agents with or without total body
irradiation and antibody-mediated lymphocyte depletion
and is required to allow engraftment of allogeneic hemato-
poietic cells. However, conditioning is associated with off-
target effects and often produces signiﬁcant alterations in
intestinal homeostasis (Figure 2). In murine models, an in-
crease in total body irradiation dose correlated with
compromised intestinal barrier function, resulting in
elevated levels of lipopolysaccharide in the serum [43]. A
similar phenomenon was conﬁrmed in patients, with in-
creases in intestinal permeability seen only after myeloa-
blative conditioning and not reduced-intensity conditioning
[44]. The presence of GVHD, in turn, further greatly com-
promises intestinal barrier function, indicating synergistic
damage to the epithelium [43].Figure 1. Fluctuations in intestinal microbial diversity reﬂect host and environmenta
and environmental factors can modulate microbiota composition. A high-fat diet can
use of probiotics restores commensal populations, and excessive tolerance leads to cThe primary mechanism driving loss of intestinal barrier
function is thought to result from cell death in the rapidly
proliferating crypt compartment of the intestinal epithelium,
leading to impaired replenishment of the villus epithelium.
Mild loss of barrier function leads to mucosal inﬂammation,
which can manifest clinically early on as nausea and later as
diarrhea and abdominal discomfort [45]. Recovery of the
intestinal epithelium from injury is dependent on repopu-
lation by intestinal stem cells, which have been found in
murinemodels to be lost in the setting of GVHD, a potentially
critical event that determines recovery from conditioning-
and inﬂammation-mediated injury [46,47]. In these models,
strategies to support epithelial cell recovery that have shown
promise for reducing GVHD include the Wnt agonist R-
spondin1 [46] and IL-22 [47].
Interestingly, the effects of GVHD on intestine-derived
antimicrobial molecules appear to be molecule-speciﬁc.
Although both a-defensins and the antimicrobial lectin
RegIIIg in the steady state are expressed by Paneth cells (and
RegIIIg by enterocytes) [48], the a-defensins are profoundly
reduced with GVHD [49], whereas RegIIIg is markedly up-
regulated [50]. The human homologue of RegIIIg, RegIIIa, is
similarly found to be elevated in the serum of patients with
intestinal GVHD [51]. How levels of antimicrobial com-
pounds are modulated by GVHD may depend on expression
patterns of the molecules.
IgA levels are also frequently reduced for many months
after HCT. Reduced IgA levels in the intestinal lumen of mice
can be seen after HCT [52] and in the serum of patients
during the ﬁrst 6 months following HCT, after which patients
generally begin to recover normal IgA levels. Those who
develop acute or chronic GVHD, however, remain IgA deﬁ-
cient [53]. In addition to impaired recovery of plasma cell
function, GVHD is associated with perturbations in addi-
tional aspects of intestinal homeostasis. IL-22eproducing
ILCs have been found to be profoundly depleted in the in-
testines of mice with GVHD [47], which may contribute to
loss of intestinal epithelial stem cells. Notably, Paneth cellsl factors. Commensal bacteria prevent overgrowth of potential pathogens. Host
lead to pathogen colonization, antibiotic use can lead to pathogen domination,
ommensal overgrowth and increased commensal diversity.
Figure 2. Transplant-related inﬂuences on the intestinal microbiota. Pre-HCT conditioning is required to allow engraftment of allogeneic hematopoietic cells.
However, conditioning is associated with off-target effects like reduction in the amount and diversity of the microbiota, mucositis, organ dysfunction, and infection.
Supportive care at this stage includes supplemental nutrition, antimicrobial therapy, and also GVHD prophylaxis. Antimicrobial prophylaxis could prevent cyto-
megalovirus (CMV), herpes simplex virus (HSV), and Pneumocystis jiroveci pneumonia (PJP) infection. Once engraftment is ongoing, the presence of GVHD further
compromises intestinal barrier function, indicating synergistic damage to the epithelium, and therapy is necessary to complement innate and adaptive immune
responses. GvL indicates graft-versus-leukemia.
M.D. Docampo et al. / Biol Blood Marrow Transplant 21 (2015) 1360e1366 1363are markedly reduced in the setting of GVHD in both murine
models [49,52] and patients [54]. Reduction in Paneth cells
was found to be prognostic for a low likelihood of response to
treatment and increased nonrelapse mortality [54].
EFFECTS OF HCT AND GVHD ON INTESTINAL
MICROBIOTA
Effects of GVHD on intestinal microbiota composition
have been examined by several groups. Murine experiments
have demonstrated that although HCT itself produces only
mild changes in microbiota composition, onset of GVHD is
associated with major ﬂuctuations, including a generalized
loss of species diversity, an expansion of members of the
bacterial orders Enterobacteriales (including Escherichia,
Klebsiella, and Enterobacter species) and Lactobacillales
(including Lactobacillus, Enterococcus, and Streptococcus
species), and a corresponding loss of obligately anaerobic
bacteria from the phylum Firmicutes, including members of
the order Clostridiales [49,52,55].
In contrast to mice, HCT alone is often associated with
major changes in microbiota composition [56]. This differ-
ence is attributed to the frequent use of antibiotics in pa-
tients undergoing HCT, whereas antibiotics are not routinely
used in murine experiments. During the course of hospital-
ization, many patients develop loss of ﬂora diversity and
concomitant oligoclonal expansions of certain bacteria.
Common expanders include Enterococcus, Streptococcus, and
various Enterobacteriales. Interestingly, expansion of these
bacteria often precedes bloodstream infection by the same
organisms [57], a previously underappreciated aspect of the
pathophysiology of neutropenic sepsis in HCT patients.
Perhaps the most signiﬁcant risk factor for developing
enterococcal expansion that could be identiﬁed was expo-
sure to metronidazole during the hospital course [56],suggesting that damage to the obligately anaerobic subset of
commensals led to impaired suppression of Enterococcus
resulting in outgrowth.
Patientswho develop GVHD after allogeneic HCT display a
characteristic shift from Clostridiales to Lactobacillales/
Enterobacteriales [52,58,59] in a manner very similar to that
seen in murine models. The etiology for these shifts in in-
testinal ﬂora composition is unclear but may be related to
changes in nutritional intake. A pattern of loss of members of
Clostridiales, including Roseburia, Faecalibacterium, Rumino-
coccus and Blautia species, can be observed in volunteers
placed on high-protein and low-carbohydrate diets [60] or
on diets derived entirely from animal products [61]. Many of
these Clostridiales perform the bulk of fermentation of
consumed no digestible carbohydrates, and their metabolites
are increasingly thought to produce health beneﬁts [62],
including induction of Tregs as described above. Thus, it is
possible that the loss of Clostridiales observed in the setting
of GVHD is maladaptive and may further contribute to
inﬂammation within the intestine.
EFFECTS OF MICROBIOTA ON GVHD
Early murine studies from the 1970s found that broadly
targeting the microbiota improved outcomes in murine
models after allogeneic HCT. Mice transplanted in germ-free
conditions [63] or receiving gut-decontaminating antibiotics
[64] developed signiﬁcantly less GVHD, demonstrating that
the microbiota contribute to the development of GVHD-
related lethality. In the 1980s, clinical trials of near-total
bacterial decontamination with skin cleansing, oral antibi-
otics, and protective isolationwere initially reported to result
in improved outcomes [65,66]. However, subsequent clinical
studies demonstrated no clear beneﬁt [67-69]. The reasons
behind these inconsistent results remain unclear but could
Figure 3. Putative roles for probiotic therapy in preventing acute GVHD.
Probiotic therapy reduces susceptibility to enteric pathogens through the
maintenance of the epithelial and commensal barriers. LPS indicates lipo-
polysaccharide; TNF-a, tumor necrosis factor-a; APC, antigen presenting cell;
TGF-b, transforming growth factor-b.
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therefore, this expensive approach was abandoned in the
early 1990s [71].
How the microbiota can modulate GVHD-mediated
inﬂammation is an area of ongoing study. The bacterial
product, lipopolysaccharide, which signals through TLR4,
was identiﬁed to be an important proinﬂammatory mediator
of GVHD [43]. The role of Toll-like receptors and MyD88/TRIF
signaling in general has been investigated by several groups
and remains controversial, with disparate results likely
dependent on speciﬁc model differences as well as the tissue
type where the role of signaling is being studied [72-74]. An
additional pathway mediating inﬂammatory responses to
the microbiota in the setting of GVHD includes the Nlrp3
inﬂammasome via production of IL-1b [75]. Recently, bac-
terial translocation into intestinal tissues after total bodyFigure 4. Microbiota homeostasis during alloHCT and proposed therapies targeting re
leading to inﬂammation and epithelial damage and are balanced by factors that pr
indicates keratinocyte growth factor; ISC, intestinal stem cells; MSC, mesenchymal stirradiation in mice was found to lead to recruitment
of neutrophils into intestinal tissues [76]. This neutrophilic
inﬁltration mediated localized tissue damage via production
of reactive oxygen species, resulting in exacerbated GVHD.
Yet not all bacterial sensing pathways are necessarily
proinﬂammatory. For example, NOD2, which functions to
recognize bacterial peptidoglycan, appears to mediate pro-
tective effects against GVHD in both mouse models [77] and
humans [78].
Efforts to identify speciﬁc pro- and anti-inﬂammatory
members of the microbiota have found that members of
Enterobacteriales and Enterococcus may be potential con-
tributors to increased GVHD in both mice [49,52] and
humans [58,59], although these ﬁndings are based on asso-
ciations, and causation as well as potential mechanisms
remain to be elucidated. Murine studies have also found that
certain intestinal lactobacilli can reduce experimental GVHD
[52,79]. Thus, replenishing the microbiota through probiotic
therapy may potentially offer a novel approach to attenu-
ating GVHD and its associated risk for bloodstream infections
(Figure 3). More severe neutropenia after nonmyeloablative
conditioning has been found to be associated with increased
GVHD and nonrelapse mortality [80]; whether neutropenia
contributes directly to GVHD or alternatively is associated
with increased use of antibiotics, which then leads to
increased GVHD, remains unclear. Notably, neutrophil
recruitment into the GI tract and subsequent oxygen radicals
may amplify tissue cytotoxicity [76].
Recently, our group reported an analysis of patient ﬂora
samples early after HCT [81]. Eighty recipients of allogeneic
HCT provided fecal samples at the time of neutrophil re-
covery, and microbial diversity, quantiﬁed by the inverse
Simpson index, was predictive of overall survival. Mortality
was particularly increased in patients with the lowest in-
testinal diversity, with overall survival rates at 3 years of 36%
in the low-diversity group, compared with 60% and 67% instoration in intestinal microbial diversity. A number of factors produce disbiosis
oduce eubiosis leading to immune regulation and epithelial restoration. KGF
em cell; SCFA, short-chain fatty acid.
M.D. Docampo et al. / Biol Blood Marrow Transplant 21 (2015) 1360e1366 1365the intermediate- and high-diversity groups, respectively.
The increase in mortality associated with lower diversity
appeared to be largely attributed to increased death due to
GVHD or infection rather than relapse or disease progression.
Whether the microbiota of the allogeneic HCT donor
could impact on outcomes after allogeneic HCT is an inter-
esting question that is not yet fully answered. Mouse models
indicate that hematopoietic grafts derived from mice raised
in germ-free conditions caused GVHD similar in severity to
grafts from conventional mice, indicating that the presence
or absence of donor microbiota does not appear to impact on
GVHD [82].Whethermore subtle changes in the composition
of the donor microbiota can modulate GVHD severity re-
mains an open question.FUTURE STRATEGIES
Recent work has resulted in a heightened appreciation for
the strength of a bidirectional relationship that exists be-
tween the intestinal microbiota and the patient at risk for
developing GVHD. Much work remains to better characterize
precisely the bacterial mediators of increased or reduced risk
for GVHD, bacterial ligands and metabolites that modulate
host tissues, and the cellular components that carry out
microbiota effects to change inﬂammatory tone (Figure 4).
These efforts should pave theway to targeting themicrobiota
in a rational way to signiﬁcantly mitigate the risk of devel-
oping GVHD in a manner that does not result in diminished
global immune function or blunting of graft-versus-tumor
effects that are critical to prevent malignant relapse.ACKNOWLEDGMENTS
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